MCRI: Study into rare side effects of COVID-19 vaccines

A new international study will examine the rare side effects caused by COVID-19 vaccines.

The University of Alberta in Canada is leading the study, through the विशेष टीकाकरण सेवाओं का अंतर्राष्ट्रीय नेटवर्क (INSIS). INSIS brings together specialist clinicians in vaccine safety, systems biology and genomics, including AusVaxSafety, to characterise the risk factors and underlying mechanism of adverse events following COVID-19 immunisation.

INSIS focuses on very rare adverse reactions, those which affect less than 0.001 % of the population, that occur after COVID-19 vaccination. This study aims to understand the causes and risk factors behind these occurrences, to ensure the development of even safer vaccines in potential future pandemics.

Read more on the Murdoch Children’s Research Institute (MCRI) website.

 

एमवीईसी: विशेष टीकाकरण सेवाओं का अंतर्राष्ट्रीय नेटवर्क

एमवीईसी: ऑसवैक्ससेफ्टी: ऑस्ट्रेलिया में वैक्सीन सुरक्षा निगरानी

MVEC: AEFI-CAN: Adverse Events Following Immunisation – Clinical Assessment Network

एमवीईसी: कोविड-19


New home for COVID-19 information

Coronavirus (COVID-19) Victoria has now moved all COVID-19 information to a new home on the Better Health Channel. Check the website for consumer and clinician information on disease prevention, testing, treatment, long covid, and special risk group advice.  

Better Health: Coronavirus (COVID-19) Victoria 


Updated immunisation reference page: COVID‑19

We have updated our COVID-19 reference page with up-to-date guidance on currently available COVID-19 vaccines, across age groups.

The newly updated page includes recommendations on the use of the new monovalent XBB.1.5 vaccines and answers to commonly asked questions relating to the new vaccines as well as other COVID-19 vaccine-related queries. 

एमवीईसी: कोविड-19


ATAGI: Recommendations on the use of the Moderna and Pfizer monovalent Omicron XBB.1.5 COVID-19 vaccines

On 20 November, ATAGI released new recommendations for the use of monovalent XBB.1.5 COVID-19 vaccines for primary vaccination and boosters, in those aged 5 and older.

The monovalent XBB.1.5 vaccines target currently circulating Omicron subvariants. This differs to the bivalent COVID-19 vaccines which offer protection against both earlier Omicron subvariants and the original strain of COVID-19.

All currently available COVID-19 vaccines provide strong protection against severe disease. Monovalent XBB.1.5 vaccines show a modest increase in protection and are therefore considered the preferred option.

People who have not received their recommended 2023 dose(s) are encouraged to be vaccinated as soon as possible. Those who have already received their 2023 dose(s) do not need revaccination with a monovalent XBB.1.5 vaccine.

The monovalent Omicron XBB.1.5 vaccines available for use in Australia are:

  • Pfizer (5 to < 12 years – light blue cap)
  • Pfizer (≥ 12 years – dark grey cap)
  • Moderna (≥ 12 years)

Eligible children under 5 years can continue to receive an age-appropriate original strain vaccines (Pfzier – maroon cap).

ATAGI statement


Australian Immunisation Handbook: New chapter on COVID-19

Today, 5 October 2023, the Department of Health and Aged Care has published a new chapter on COVID-19 in the Australian Immunisation Handbook.

In a major update, the new COVID-19 disease chapter consolidates the available COVID-19 clinical guidance material.

The chapter includes the following subsections:

  • Overview 
  • Recommendations 
  • Vaccines, dosage and administration 
  • मतभेद और सावधानियां 
  • Adverse events 
  • Nature of the disease 
  • Clinical features 
  • एपिडेमियोलॉजी 
  • Vaccine information 
  • Transporting, storing and handling vaccines 
  • Public health management 
  • Variations from product information. 

Australian Immunisation Handbook: COVID-19


Misinterpretation and misuse of recent COVID-19 study

The Murdoch Children’s Research Institute (MCRI) authors of a recent COVID-19 study have released a statement addressing the misinterpretation and misuse of their publication, BNT162b2 COVID-19 vaccination in children alters cytokine responses to heterologous pathogens and Toll-like receptor agonists.

The publication has been used to claim that COVID-19 vaccines are dangerous and that they suppress the immune system. The research does not provide any evidence to suggest that COVID-19 vaccines are harmful to the immune system of children or adults.

MCRI: A statement regarding a recent COVID-19 vaccination publication


Decommission of COVID-19 Vaccination Training Program

The COVID-19 Vaccination Training Program was decommissioned on 30 September 2023. From January 2021 to September 2023, successful completion of this program was mandatory for all providers delivering COVID-19 vaccines.

In Victoria, Secretary Approval from 1 October allows nurse immunisers and pharmacist immunisers to independently deliver COVID-19 vaccines, in addition to medical practitioners. Aboriginal and Torres Strait Islander health practitioner immunisers can administer COVID-19 vaccines under the written instruction of a medical practitioner, nurse practitioner or authorised midwife.

Read more on the Victorian Department of Health COVID-19 vaccine page.


BMJ: Considerations for vaccinating children against COVID-19

In July, BMJ published a literature review led by researchers at the Murdoch Children’s Research Institute (MCRI) including MVEC Director Prof Nigel Crawford. The paper describes COVID-19 in children, with a focus on low-income and middle-income countries, and summarises the published literature on safety, efficacy and effectiveness of COVID-19 vaccination in children and adolescents.

The review emphasises that at-risk groups should be prioritised for COVID-19 vaccination. According to the review, COVID-19 vaccines are effective against severe COVID-19 in children and adolescents, although there is limited additional benefit in healthy children given widespread infection-derived immunity.

For more information, access the publication and accompanying MCRI news story below.

BJM Paediatrics Open: Considerations for vaccinating children against COVID-19
MCRI: COVID-19 vaccines are effective against severe cases in children


Updated monovalent mRNA COVID-19 vaccines approved by FDA

On 11 September, the United States Food and Drug Administration (FDA) approved COVID-19 vaccines updated to include a monovalent component that targets currently circulating variants.

Bivalent Moderna and Pfizer COVID-19 vaccines are no longer authorised for use in the US.

In Australia, bivalent COVID-19 vaccines (those which target the original/ancestral strain of the virus as well as an Omicron subvariant) continue to be recommended for primary vaccination and boosters in people aged 12 years and older.

Read more in the FDA’s press release: FDA: Updated mRNA COVID-19 vaccines

Current ATAGI advice on bivalent COVID-19 vaccines:
ATAGI: Recommendations on use of the Pfizer bivalent COVID-19 vaccine (February 2023) 
ATAGI: Recommendations on use of the Moderna bivalent COVID-19 vaccine (February 2023) 
ATAGI: Advice on the preferential use of bivalent COVID-19 vaccines for primary vaccination of people aged 12 years or older (May 2023) 

एमवीईसी: कोविड-19 


ATAGI: Update on the COVID-19 vaccination program

On 1 September 2023, ATAGI updated its recommendations for additional COVID-19 vaccines doses. An additional 2023 dose is recommended for everyone aged 75 and over (if 6 months have passed since their last dose). 

Everyone aged 65 to 75 and people aged 18 to 64 with severe immunocompromise should consider an additional 2023 dose (if 6 months have passed since their last dose). 

In February 2023, ATAGI recommended COVID-19 boosters for everyone aged over 65 and for people aged 18 to 64 with severe immunocompromise (if 6 months have passed since their last dose). People who were recommended to receive a booster in February and who have not yet had one should receive an additional dose as soon as possible. 

ATAGI: Update on the COVID-19 vaccination program